These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37584424)

  • 1. Identification of Novel Quinolin-2(1
    Zhang B; Yang YY; Zhao ZJ; Liu RD; Feng LL; Jiang MY; Yuan Y; Huang S; Li Z; Wang Q; Luo HB; Wu Y
    J Med Chem; 2023 Sep; 66(17):12468-12478. PubMed ID: 37584424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
    Huang MX; Tian YJ; Han C; Liu RD; Xie X; Yuan Y; Yang YY; Li Z; Chen J; Luo HB; Wu Y
    J Med Chem; 2022 Jun; 65(12):8444-8455. PubMed ID: 35666471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia.
    Le ML; Yang YY; Jiang MY; Han C; Guo ZR; Liu RD; Zhao ZJ; Zhou Q; Wen S; Wu Y
    Bioorg Chem; 2024 Mar; 144():107114. PubMed ID: 38224637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction.
    Wennogle LP; Hoxie H; Peng Y; Hendrick JP
    Adv Neurobiol; 2017; 17():349-384. PubMed ID: 28956339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
    Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis.
    Zhao ZJ; Jiang MY; Huang MX; Yang YY; Feng LL; Zhang C; Huang YY; Luo HB; Wu Y
    J Med Chem; 2024 May; 67(10):8309-8322. PubMed ID: 38669059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotides and phosphodiesterases and airway function.
    Barnes PJ
    Eur Respir J; 1995 Mar; 8(3):457-62. PubMed ID: 7789494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
    Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
    J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxation of isolated guinea-pig trachea by apigenin, a constituent of celery, via inhibition of phosphodiesterase.
    Chen JL; Ko WC
    Eur J Pharmacol; 2017 Sep; 811():129-133. PubMed ID: 28603044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase genes and antidepressant treatment response: a review.
    Esposito K; Reierson GW; Luo HR; Wu GS; Licinio J; Wong ML
    Ann Med; 2009; 41(3):177-85. PubMed ID: 18932104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization.
    Delpy E; le Monnier de Gouville AC
    Br J Pharmacol; 1996 Jul; 118(6):1377-84. PubMed ID: 8832060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
    Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
    Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle.
    Qiu Y; Kraft P; Craig EC; Liu X; Haynes-Johnson D
    Urology; 2002 Jan; 59(1):145-9. PubMed ID: 11796312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic potential of phosphodiesterase inhibitors.
    Perry MJ; Higgs GA
    Curr Opin Chem Biol; 1998 Aug; 2(4):472-81. PubMed ID: 9736920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.